TriStar Technology Group
TriStar Technology Group LLC is a biotechnology company specializing in providing high-quality human biospecimens and integrated biomarker services to accelerate oncology therapeutic development. Their offerings include ethically approved anonymized clinical samples such as FFPE blocks, tissue microarrays (TMAs), double spun plasma, and buffy coat, all annotated with histopathological, molecular, and clinical follow-up data. TriStar serves pharmaceutical, biotech, diagnostics, and AI companies by supplying samples suitable for IHC, RNA-ISH, NGS, and multiplex assays, alongside expert contract research services including IHC assay development, RNAScope, NGS, RNA-Seq, digital spatial profiling, and digital image analysis. Their business model is based on providing fit-for-purpose biospecimens combined with expert CRO capabilities, supporting research applications in immuno-oncology, targeted cancer therapeutics, antibody-drug conjugates, and prevalence studies. The company is positioned as a key resource for oncology R&D with a repository built for robust assay performance and biomarker research, leveraging collaborations with leading medical centers in Western Europe and the UK.
TriStar Technology Group
TriStar Technology Group LLC is a biotechnology company specializing in providing high-quality human biospecimens and integrated biomarker services to accelerate oncology therapeutic development. Their offerings include ethically approved anonymized clinical samples such as FFPE blocks, tissue microarrays (TMAs), double spun plasma, and buffy coat, all annotated with histopathological, molecular, and clinical follow-up data. TriStar serves pharmaceutical, biotech, diagnostics, and AI companies by supplying samples suitable for IHC, RNA-ISH, NGS, and multiplex assays, alongside expert contract research services including IHC assay development, RNAScope, NGS, RNA-Seq, digital spatial profiling, and digital image analysis. Their business model is based on providing fit-for-purpose biospecimens combined with expert CRO capabilities, supporting research applications in immuno-oncology, targeted cancer therapeutics, antibody-drug conjugates, and prevalence studies. The company is positioned as a key resource for oncology R&D with a repository built for robust assay performance and biomarker research, leveraging collaborations with leading medical centers in Western Europe and the UK.